Details of the Drug

General Information of Drug (ID: DM471KJ)

Drug Name
Omeprazole
Synonyms Losec (TN)
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [1]
Gastric ulcer DA60 Approved [1]
Gastrinoma 2C10.1 Approved [1]
Gastroesophageal reflux disease DA22.Z Approved [2]
Laryngeal disorder N.A. Approved [1]
Nausea MD90 Approved [1]
Peptic esophagitis N.A. Approved [1]
Peptic ulcer DA61 Approved [1]
Congenital laryngomalacia N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antiulcer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 345.4
Logarithm of the Partition Coefficient (xlogp) 2.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 30-40% []
Clearance
The total body clearance of drug is 500-600 mL/min []
Elimination
Most of the dose (about 77%) was eliminated in urine as at least six different metabolites []
Half-life
The concentration or amount of drug in body reduced by one-half in 0.5 - 1 hour []
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.79 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [5]
Vd
The volume of distribution (Vd) of drug is 0.3 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.5 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Gastric pH decreased Not Available ATP12A OTSQSKEK [7]
Chemical Identifiers
Formula
C17H19N3O3S
IUPAC Name
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
Canonical SMILES
CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
InChI
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
InChIKey
SUBDBMMJDZJVOS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4594
ChEBI ID
CHEBI:77260
CAS Number
73590-58-6
DrugBank ID
DB00338
TTD ID
D01XNB
VARIDT ID
DR00387
INTEDE ID
DR1196
ACDINA ID
D00489
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric H(+)/K(+) ATPase (Proton pump) TTLOKXP ATP4A_HUMAN ; ATP4B_HUMAN Modulator [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [13]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alcohol dehydrogenase 1C (ADH1C) OTO1DV7F ADH1G_HUMAN Gene/Protein Processing [14]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Gene/Protein Processing [14]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [15]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Gene/Protein Processing [16]
Aryl hydrocarbon receptor nuclear translocator (ARNT) OTMSIEZY ARNT_HUMAN Protein Interaction/Cellular Processes [16]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [17]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [18]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Gene/Protein Processing [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [19]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Protein Interaction/Cellular Processes [19]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Omeprazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cefuroxime DMSIMD8 Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Cefuroxime. Acute bronchitis [CA42] [20]
Glibenclamide DM8JXPZ Minor Decreased metabolism of Omeprazole caused by Glibenclamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [21]
Tolazamide DMIHRNA Minor Decreased metabolism of Omeprazole caused by Tolazamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [21]
Acetohexamide DMR6N7H Minor Decreased metabolism of Omeprazole caused by Acetohexamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [21]
Glipizide DMZA5PQ Minor Decreased metabolism of Omeprazole caused by Glipizide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [21]
Arn-509 DMT81LZ Moderate Increased metabolism of Omeprazole caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [22]
Framycetin DMF8DNE Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Framycetin. Alcoholic liver disease [DB94] [23]
Paromomycin DM1AGXN Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Paromomycin. Amoebiasis [1A36] [23]
Isosorbide dinitrate DMBI4JG Minor Altered absorption of Omeprazole caused by Isosorbide dinitrate. Anal fissure/fistula [DB50] [24]
Clorazepate DMC3JST Moderate Decreased metabolism of Omeprazole caused by Clorazepate mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [25]
Alprazolam DMC7XDN Moderate Decreased metabolism of Omeprazole caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [25]
Halazepam DMPFWO6 Moderate Decreased metabolism of Omeprazole caused by Halazepam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [25]
Chlordiazepoxide DMTN5XI Moderate Decreased metabolism of Omeprazole caused by Chlordiazepoxide mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [25]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Omeprazole caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [26]
Cilostazol DMZMSCT Major Decreased metabolism of Omeprazole caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [22]
Voriconazole DMAOL2S Moderate Decreased metabolism of Omeprazole caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [27]
Posaconazole DMUL5EW Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Posaconazole. Aspergillosis [1F20] [28]
Kanamycin DM2DMPO Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Kanamycin. Bacterial infection [1A00-1C4Z] [23]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [29]
Clarithromycin DM4M1SG Minor Decreased metabolism of Omeprazole caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [30]
Amikacin DM5PDRB Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Amikacin. Bacterial infection [1A00-1C4Z] [23]
Streptomycin DME1LQN Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Streptomycin. Bacterial infection [1A00-1C4Z] [23]
Cefpodoxime DMJUNY5 Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [20]
Gentamicin DMKINJO Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Gentamicin. Bacterial infection [1A00-1C4Z] [23]
Bacampicillin DMP54C7 Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [20]
Netilmicin DMRD1QK Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Netilmicin. Bacterial infection [1A00-1C4Z] [23]
Cefditoren DMSUVM1 Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Cefditoren. Bacterial infection [1A00-1C4Z] [31]
Tobramycin DMUI0CH Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Tobramycin. Bacterial infection [1A00-1C4Z] [23]
Vismodegib DM5IXKQ Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Vismodegib. Basal cell carcinoma [2C32] [32]
Pexidartinib DMS2J0Z Major Decreased absorption of Omeprazole due to altered gastric pH caused by Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [33]
Lapatinib DM3BH1Y Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Lapatinib. Breast cancer [2C60-2C6Y] [22]
HKI-272 DM6QOVN Major Decreased absorption of Omeprazole due to altered gastric pH caused by HKI-272. Breast cancer [2C60-2C6Y] [32]
Bosutinib DMTI8YE Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Bosutinib. Breast cancer [2C60-2C6Y] [34]
Atorvastatin DMF28YC Moderate Decreased clearance of Omeprazole and Atorvastatin due to competitive inhibition of the same transporter. Cardiovascular disease [BA00-BE2Z] [35]
Anisindione DM2C48U Moderate Decreased metabolism of Omeprazole caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [36]
Panitumumab DMQPD1F Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Panitumumab. Colorectal cancer [2B91] [23]
Levobupivacaine DM783CH Minor Increased metabolism of Omeprazole caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [37]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Omeprazole caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [38]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Omeprazole caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [39]
MK-8228 DMOB58Q Moderate Increased metabolism of Omeprazole caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [40]
Duloxetine DM9BI7M Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Duloxetine. Depression [6A70-6A7Z] [41]
Escitalopram DMFK9HG Moderate Decreased metabolism of Omeprazole caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [42]
Nitroglycerin DMQ2491 Minor Altered absorption of Omeprazole caused by Nitroglycerin. Diabetic foot ulcer [BD54] [24]
Diazepam DM08E9O Moderate Decreased metabolism of Omeprazole caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Omeprazole caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Cenobamate DM8KLU9 Moderate Decreased metabolism of Omeprazole caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Omeprazole caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Omeprazole caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Clonazepam DMTO13J Moderate Decreased metabolism of Omeprazole caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Phenobarbital DMXZOCG Minor Decreased metabolism of Omeprazole caused by Phenobarbital mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Cannabidiol DM0659E Minor Decreased metabolism of Omeprazole caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [22]
Bendroflumethiazide DM7EVLC Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Bendroflumethiazide. Essential hypertension [BA00] [23]
Itraconazole DMCR1MV Moderate Decreased metabolism of Omeprazole caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [46]
Pentamidine DMHZJCG Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Pentamidine. Fungal infection [1F29-1F2F] [23]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Omeprazole caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [46]
Amphotericin B DMTAJQE Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Amphotericin B. Fungal infection [1F29-1F2F] [23]
Chlorothiazide DMLHESP Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Chlorothiazide. Heart failure [BD10-BD1Z] [23]
Furosemide DMMQ8ZG Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Furosemide. Heart failure [BD10-BD1Z] [23]
Digoxin DMQCTIH Moderate Decreased clearance of Omeprazole due to the transporter inhibition by Digoxin. Heart failure [BD10-BD1Z] [44]
Bumetanide DMRV7H0 Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Bumetanide. Heart failure [BD10-BD1Z] [23]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Hydroflumethiazide. Heart failure [BD10-BD1Z] [23]
Rifampin DMA8J1G Moderate Increased metabolism of Omeprazole caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [32]
Delavirdine DM3NF5G Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Delavirdine. Human immunodeficiency virus disease [1C60-1C62] [47]
Fosamprenavir DM4W9B3 Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Fosamprenavir. Human immunodeficiency virus disease [1C60-1C62] [48]
Tipranavir DM8HJX6 Moderate Increased metabolism of Omeprazole caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Rilpivirine DMJ0QOW Major Decreased absorption of Omeprazole due to altered gastric pH caused by Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [49]
Atazanavir DMSYRBX Major Decreased absorption of Omeprazole due to altered gastric pH caused by Atazanavir. Human immunodeficiency virus disease [1C60-1C62] [32]
Raltegravir DMYURI6 Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Raltegravir. Human immunodeficiency virus disease [1C60-1C62] [50]
Isosorbide mononitrate DMYLMU0 Minor Altered absorption of Omeprazole caused by Isosorbide mononitrate. Hydrocephalus [8D64] [24]
Simvastatin DM30SGU Moderate Decreased clearance of Omeprazole and Simvastatin due to competitive inhibition of the same transporter. Hyper-lipoproteinaemia [5C80] [35]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Omeprazole caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [32]
Indapamide DMGN1PW Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Indapamide. Hypertension [BA00-BA04] [23]
Trichlormethiazide DMHAQCO Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Trichlormethiazide. Hypertension [BA00-BA04] [23]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Hydrochlorothiazide. Hypertension [BA00-BA04] [23]
Levothyroxine DMHN027 Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Levothyroxine. Hypo-thyroidism [5A00] [32]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Omeprazole caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [22]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Omeprazole caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
Triazolam DMETYK5 Moderate Decreased metabolism of Omeprazole caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Omeprazole caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [51]
Quazepam DMY4D87 Moderate Decreased metabolism of Omeprazole caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
Estazolam DMZGXUM Moderate Decreased metabolism of Omeprazole caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
Iron DMAP8MV Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Iron. Iron deficiency anaemia [3A00] [52]
Ceritinib DMB920Z Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Ceritinib. Lung cancer [2C25] [53]
Erlotinib DMCMBHA Major Decreased absorption of Omeprazole due to altered gastric pH caused by Erlotinib. Lung cancer [2C25] [32]
Dacomitinib DMOH8VY Major Decreased absorption of Omeprazole due to altered gastric pH caused by Dacomitinib. Lung cancer [2C25] [22]
Selpercatinib DMZR15V Major Decreased absorption of Omeprazole due to altered gastric pH caused by Selpercatinib. Lung cancer [2C25] [22]
Quinine DMSWYF5 Minor Decreased metabolism of Omeprazole caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [54]
IPI-145 DMWA24P Moderate Decreased metabolism of Omeprazole caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [55]
Acalabrutinib DM7GCVW Major Decreased absorption of Omeprazole due to altered gastric pH caused by Acalabrutinib. Mature B-cell lymphoma [2A85] [56]
Ponatinib DMYGJQO Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Ponatinib. Mature B-cell lymphoma [2A85] [32]
Arry-162 DM1P6FR Moderate Increased metabolism of Omeprazole caused by Arry-162 mediated induction of CYP450 enzyme. Melanoma [2C30] [32]
Flibanserin DM70DTN Moderate Decreased metabolism of Omeprazole caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [57]
Riluzole DMECBWN Minor Increased metabolism of Omeprazole caused by Riluzole mediated induction of CYP450 enzyme. Motor neuron disease [8B60] [58]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Omeprazole caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Nilotinib DM7HXWT Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Nilotinib. Myeloproliferative neoplasm [2A20] [59]
Dasatinib DMJV2EK Major Decreased absorption of Omeprazole due to altered gastric pH caused by Dasatinib. Myeloproliferative neoplasm [2A20] [60]
Prasugrel DM7MT6E Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Prasugrel. Myocardial infarction [BA41-BA43] [61]
Modafinil DMYILBE Moderate Decreased metabolism of Omeprazole caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [32]
Metolazone DMB39LO Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Metolazone. Oedema [MG29] [23]
Polythiazide DMCH80F Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Polythiazide. Oedema [MG29] [23]
Valdecoxib DMAY7H4 Minor Decreased metabolism of Omeprazole caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [62]
Naproxen DMZ5RGV Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Naproxen. Osteoarthritis [FA00-FA05] [63]
Carboplatin DMG281S Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Carboplatin. Ovarian cancer [2C73] [23]
Aspirin DM672AH Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Aspirin. Pain [MG30-MG3Z] [64]
Abametapir DM2RX0I Moderate Decreased metabolism of Omeprazole caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [65]
Lefamulin DME6G97 Moderate Decreased metabolism of Omeprazole caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [66]
Choline salicylate DM8P137 Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Choline salicylate. Postoperative inflammation [1A00-CA43] [64]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Omeprazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [67]
Enzalutamide DMGL19D Moderate Increased metabolism of Omeprazole caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [68]
Ambrisentan DMD1QXW Minor Decreased metabolism of Omeprazole caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [69]
Riociguat DMXBLMP Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Riociguat. Pulmonary hypertension [BB01] [70]
Axitinib DMGVH6N Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Axitinib. Renal cell carcinoma [2C90] [71]
Salsalate DM13P4C Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Salsalate. Rheumatoid arthritis [FA20] [64]
Tofacitinib DMBS370 Moderate Decreased metabolism of Omeprazole caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [32]
Clozapine DMFC71L Moderate Increased metabolism of Omeprazole caused by Clozapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [72]
Salicyclic acid DM2F8XZ Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Salicyclic acid. Seborrhoeic dermatitis [EA81] [64]
Larotrectinib DM26CQR Moderate Decreased metabolism of Omeprazole caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [32]
Armodafinil DMGB035 Moderate Decreased metabolism of Omeprazole caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [32]
Cisplatin DMRHGI9 Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [23]
Vandetanib DMRICNP Minor Decreased absorption of Omeprazole due to altered gastric pH caused by Vandetanib. Solid tumour/cancer [2A00-2F9Z] [32]
Warfarin DMJYCVW Moderate Decreased metabolism of Omeprazole caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [36]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Omeprazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [73]
Clopidogrel DMOL54H Major Decreased metabolism of Omeprazole caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [74]
Mycophenolate mofetil DMPQAGE Moderate Decreased absorption of Omeprazole due to altered gastric pH caused by Mycophenolate mofetil. Transplant rejection [NE84] [75]
Tolbutamide DM02AWV Minor Decreased metabolism of Omeprazole caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [21]
Chlorpropamide DMPHZQE Minor Decreased metabolism of Omeprazole caused by Chlorpropamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [21]
Plazomicin DMKMBES Moderate Increased risk of hypomagnesemia by the combination of Omeprazole and Plazomicin. Urinary tract infection [GC08] [23]
⏷ Show the Full List of 127 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Carminic acid E00506 10255083 Colorant
Cetyl alcohol E00061 2682 Coating agent; Emollient; Emulsifying agent; Stiffening agent
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydroxyethylamine E00022 700 Alkalizing agent; Emulsifying agent; Solvent
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Meglumine E00181 8567 Buffering agent
Menthol E00050 1254 Flavoring agent
Monoethanolamine lauryl sulfate E00377 78449 Surfactant
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Potassium chloride E00074 4873 Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearate E00453 2724691 Emulsifying agent; Gelling agent; Glidant; Modified-release agent; Stiffening agent; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Acetone E00004 180 Solvent
Aluminum chlorohydrex propylene glycol E00594 71587575 Other agent
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dibutyl sebacate E00160 7986 Plasticizing agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Glyceryl behenate E00481 5362585 Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate E00537 22477175 Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA E00607 135423095 Colorant
Magnesium hydroxide E00374 73981 Adsorbent; Buffering agent
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate E00208 11177 lubricant
Poloxamer 407 E00646 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate E00395 110800 Emollient; Opacifying agent; Surfactant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium phosphate dibasic dihydrate E00498 6451167 Buffering agent; Complexing agent
Sodium phosphate tribasic dodecahydrate E00348 61473 Buffering agent; Complexing agent
Sucrose 1,6-distearate E00593 71587490 Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 62 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Omeprazole 20 mg tablet 20 mg Delayed Release Oral Tablet Oral
Omeprazole 40 mg capsule 40 mg Delayed Release Capsule Oral
Omeprazole 20 mg capsule 20 mg Delayed Release Capsule Oral
Omeprazole 10 mg capsule 10 mg Delayed Release Oral Capsule Oral
Omeprazole 20 mg capsule 20 mg Delayed Release Oral Capsule Oral
Omeprazole 40 mg capsule 40 mg Delayed Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Omeprazole FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4279).
3 BDDCS applied to over 900 drugs
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Cederberg C, Andersson T, Skanberg I: Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989;166:33-40; discussion 41-2.
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.
12 Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009 Apr;37(4):821-6.
13 Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
14 Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
15 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
16 Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
17 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
18 A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol. 2010 Dec 1;80(11):1754-61.
19 Omeprazole induces apoptosis in normal human polymorphonuclear leucocytes. Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):73-85. doi: 10.1177/039463200802100109.
20 Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
21 Humphries TJ "Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole." Dig Dis Sci 36 (1991): 1665-9. [PMID: 1748033]
22 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
23 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
24 Kajinami K, Mabuchi H "Omeprazole and diminished antianginal drug delivery." Ann Intern Med 121 (1994): 385-6. [PMID: 8042836]
25 Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P "Effect of omeprazole and cimetidine on plasma diazepam levels." Eur J Clin Pharmacol 39 (1990): 51-4. [PMID: 2276389]
26 Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
27 Eiden C, Peyriere H, Tichit R, et al. "Inherited long QT syndrome revealed by antifungals drug-drug interaction." J Clin Pharm Ther 32 (2007): 321-4. [PMID: 17489884]
28 Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
29 Product Information. Cipro XR (ciprofloxacin). Bayer Pharmaceutical Inc, West Haven, CT.
30 Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW "Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state." Antimicrob Agents Chemother 39 (1995): 2078-83. [PMID: 8540719]
31 Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
32 Cerner Multum, Inc. "Australian Product Information.".
33 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
34 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35 Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
36 Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
37 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
38 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
39 Cerner Multum, Inc. "Canadian Product Information.".
40 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
41 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
42 Canadian Pharmacists Association.
43 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
44 Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212. [PMID: 1764870]
45 Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
46 Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
47 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
48 Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
49 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
50 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
51 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
52 Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
53 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
54 Zhao XJ, Ishizaki T "A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (K-i) and type of inhibition." Eur J Drug Metab Pharm 24 (1999): 272-8. [PMID: 10716067]
55 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
56 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
57 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
58 Product Information. Rilutek (riluzole). Rhone-Poulenc Rorer, Collegeville, PA.
59 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
61 Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
62 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
63 Product Information. Naprosyn (naproxen). Syntex Laboratories Inc, Palo Alto, CA.
64 Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
65 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
66 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
67 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
68 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
69 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
70 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
71 Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
72 Frick A, Kopitz J, Bergemann N "Omeprazole reduces clozapine plasma concentrations. A case report." Pharmacopsychiatry 36 (2003): 121-3. [PMID: 12806570]
73 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
74 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
75 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.